Inhibitor Development
- 16 May 2008
- journal article
- Published by Wiley in Haemophilia
- Vol. 14 (s3) , 36-42
Abstract
Summary. The immune response to factor VIII and the development of inhibitory antibodies is a complex multi‐factorial process involving a variety of immune regulatory genes and cells, several of which have the potential to determine risk. A better understanding of the mechanisms involved will increase the likelihood of development of new therapeutic options for patients with hemophilia. This review summarizes genetic and non‐genetic risk factors currently under evaluation, and the potential modulative effect of the von Willebrand factor on factor VIII immuno‐ and antigenicity. In addition, the role of T‐regulatory cells in the pathogenicity of inhibitors will be discussed.Keywords
This publication has 53 references indexed in Scilit:
- Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia AHaematologica, 2007
- Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transferBlood, 2007
- A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levelsBlood, 2007
- Immune deviation by mucosal antigen administration suppresses gene-transfer–induced inhibitor formation to factor IXBlood, 2006
- Assessing the risk of inhibitor formation with different factor VIII productsBlood, 2006
- Regulatory/suppressor T cells in health and diseaseArthritis & Rheumatism, 2004
- Epitope repertoire of human CD4 T cells on the A3 domain of coagulation factor VIIIJournal of Thrombosis and Haemostasis, 2004
- The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia ANew England Journal of Medicine, 2002
- von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patientsHaemophilia, 2001
- Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIIIHaemophilia, 2001